# US 2020/0347032 A1 · Estrogen receptor-modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347032 A1
- Document ID: US20200347032A1
- Status: Published application
- Kind: A1
- Application number: 16/963,794
- Filed: 2019-01-22
- Published: 2020-11-05
- Earliest claimed: 2018-01-22
- Assignees: Radius Pharmaceuticals, Inc.
- Applicants: Radius Pharmaceuticals, Inc.
- Inventors: Chris Miller
- Web page: https://patentgrep.com/patent/US20200347032A1

## CPC

- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07C 43/23: containing hydroxy or O-metal groups
- C07C 43/253: containing hydroxy or O-metal groups
- C07C 215/64: with rings other than six-membered aromatic rings being part of the carbon skeleton
- C07D 209/30: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D 313/08: condensed with one six-membered ring
- C07D 333/64: Oxygen atoms
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 487/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07C 2601/02: with a three-membered ring
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

## Claims

### Claim 1

A compound according to formula I′
wherein:
B is nitrogen or carbon;
D is carbon;
A is a fused ring system selected from the group consisting of:
each Re is independently selected from hydrogen, halogen, OH, O(CO)R, O(CO)NR1R2, OPO3, OSO3, O(SO2)NR1R2, or wherein two adjacent Re together form:
R is C1-C6 alkyl or aryl;
R1 and R2 are each independently hydrogen or C1-C6 alkyl;
each R3 is hydrogen, C1-C12 acyl; C1-C12 acyloxy;
each R4 is independently hydrogen, C1-C3 alkyl, fluorine or chlorine;
each Rh is independently selected from hydrogen or CH3;
Rg is hydrogen, C1-C3 alkyl, C1-C3 fluoroalkyl, CN, fluorine, chlorine or bromine;
each Ra is independently selected from: H, C1-C3 alkyl, C1-C3 fluoroalkyl, phenyl (optionally substituted with 1-3 groups selected from fluorine, chlorine, C1-C3 alkyl, CN, OC1-C3 alkyl, OH), OH, OC1-3alkyl, CN, fluorine, chlorine, O(CO)R, O(CO)NR1R2, OPO3, OSO3, O(SO2)NR1R2, or two adjacent Ra together form:
X is O, S, CH2, NH or a bond when B is carbon, or CH2 or a bond when B is nitrogen;
Y and Z are each independently selected from CRf or N;
U and V are each independently selected from CRa or N;
each Rf is independently H, C1-C3 alkyl, OC1-C3 alkyl, fluorine or chlorine; and
W is —CHR′—CHR′—NH—C1-C4alkyl, —CHR′—CHR′—NH—C1-C4fluoroalkyl, —CHR′—CHR′—NH—C3-C6cycloalkyl, —CHR′—CHR′—NH—C1-C4alky-C3-C6cycloalkyl,
wherein each R′ is independently H or C1-C3alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein W is —CH2—CH2—NH—CH2—CH2—CH3; —CH2—CH2—NH—CH2—CH2—CH2F;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein A is:

### Claim 4 (depends on 1)

The compound of claim 1, wherein Y and Z are each CRf and U and V are each CRa.

### Claim 5 (depends on 1)

The compound of claim 1, having a structure according to formula II′
wherein:
each Ra is independently selected from H, C1-C3 alkyl, phenyl (optionally substituted with 1-3 groups selected from fluorine, chlorine, C1-C3 alkyl, CN, OC1-C3 alkyl, OH), OH, OC1-3alkyl, CN, fluorine, chlorine, O(CO)R, O(CO)NR1R2, OPO3, OSO3, O(SO2)NR1R2, or two adjacent Ra together form:
R is C1-C6 alkyl or aryl;
R1 and R2 are each independently hydrogen or C1-C6 alkyl;
each R3 is independently hydrogen; C1-C12 acyl or C1-C12 acyloxy;
each R4 is independently hydrogen, C1-C3 alkyl, fluorine or chlorine;
each Re is independently selected from hydrogen, halogen, OH, O(CO)R, O(CO)NR1R2, OPO3, OSO3, O(SO2)NR1R2, or wherein two adjacent Re together form:
each Rf is independently H, C1-C3 alkyl, OC1-C3 alkyl, fluorine or chlorine;
Rg is hydrogen, C1-C3 alkyl, C1-C3 fluoroalkyl, CN, fluorine, chlorine or bromine;
X is CH2 or a bond;
Y and Z are each independently selected from CRf or N;
U and V are each independently selected from CRa or N; and
W is —CHR′—CHR′—NH—C1-C4alkyl, —CHR′—CHR′—NH—C1-C4fluoroalkyl, —CHR′—CHR′—NH—C3-C6cycloalkyl, —CHR′—CHR′—NH—C1-C4alkyl-C3-C6cycloalkyl,
wherein each R′ is independently H or C1-C3alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein: X is CH2; Y and Z are each CRf; U and V are each CRa; Rg is F, Cl or CH3; each Ra is independently selected from H, OH, CH3 and Cl; each Rf is H; and W is —CH2—CH2—NH—CH2—CH2—CH3, —CH2—CH2—NH—CH2—CH2—CH2F,
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The compound of claim 6, wherein each Re is independently selected from hydrogen or OH, or wherein two adjacent Re together form:
and wherein R3 is H and R4 is H.

### Claim 8 (depends on 1)

The compound of claim 1, having a structure according to formula III′:
wherein: Q is H or F; Rg is F, Cl, or CH3; Ra is CH3, Cl or OMe; and Ra′ is H, F or OH; or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The compound of claim 8, wherein Rg is F.

### Claim 10 (depends on 9)

The compound of claim 9, wherein Ra is CH3 and Ra′ is H.

### Claim 11 (depends on 1)

The compound of claim 1, having a structure according to formula IV′:
wherein: Q is H or F; Rg is F, Cl, or CH3; Ra is CH3, Cl or OMe; and Ra′ is H, F or OH; or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The compound of claim 11, wherein Rg is F.

### Claim 13 (depends on 12)

The compound of claim 12, wherein Ra is CH3 and Ra′ is H.

### Claim 14 (depends on 1)

The compound of claim 1, having a structure according to formula V′:
wherein: Q is H or F; Rg is F, Cl, or CH3; Ra is CH3, Cl or OMe; and Ra′ is H, F or OH; or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The compound of claim 14, wherein Rg is F.

### Claim 16 (depends on 15)

The compound of claim 15, wherein Ra is CH3 and Ra′ is H.

### Claim 17 (depends on 1)

The compound of claim 1, having a structure according to formula VI′:
wherein: Q is H or F; Rg is F, Cl, or CH3; Ra is CH3, Cl or OMe; and Ra′ is H, F or OH; or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The compound of claim 17, wherein Rg is F.

### Claim 19 (depends on 18)

The compound of claim 18, wherein Ra is CH3 and Ra′ is H.

### Claim 20 (depends on 1)

The compound of claim 1, having a structure according to formula VII′:
wherein: Q is H or F; Ra is CH3, Cl or OMe; and Ra′ is H, F or OH; or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The compound of claim 20, wherein Ra is CH3 and Ra′ is H.

### Claim 22 (depends on 1)

The compound of claim 1, having a structure according to formula VIII′:
wherein: Q is H or F; Ra is CH3, Cl or OMe; and Ra′ is H, F or OH; or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

The compound of claim 22, wherein Ra is CH3 and Ra′ is H.

### Claim 24 (depends on 1)

The compound of claim 1, having a structure according to formula IX′:
wherein: Q is H or F; Ra is CH3, Cl or OMe; and Ra′ is H, F or OH; or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

The compound of claim 24, wherein Ra is CH3 and Ra′ is H.

### Claim 26 (depends on 1)

The compound of claim 1, having a structure according to formula X′:
wherein: Q is H or F; Ra is CH3, Cl or OMe; and Ra′ is H, F or OH; or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The compound of claim 26, wherein Ra is CH3 and Ra′ is H.

### Claim 28

A compound selected from:
1-(4-(2-(Ethylamino)ethyl)benzyl)-2-(4-methoxyphenyl)-3-methyl-1H-indol-5-ol;
1-(4-(2-(Cyclopropylamino)ethyl)benzyl)-2-(4-methoxyphenyl)-3-methyl-1H-indol-5-ol;
1-(4-(2-(Isopropylamino)ethyl)benzyl)-2-(4-methoxyphenyl)-3-methyl-1H-indol-5-ol;
1-(4-(2-(Cyclohexylamino)ethyl)benzyl)-2-(4-methoxyphenyl)-3-methyl-H-indol-5-ol;
2-(4-Methoxyphenyl)-3-methyl-1-(4-(2-((2,2,2-trifluoroethyl)amino)ethyl)benzyl)-1H-indol-5-ol;
1-(4-(2-(Cyclopropylamino)ethyl)benzyl)-3-fluoro-2-(4-methoxyphenyl)-1H-indol-5-ol;
1-(4-(2-(Ethylamino)ethyl)benzyl)-3-fluoro-2-(4-methoxyphenyl)-1H-indol-5-ol;
3-Chloro-1-(4-(2-(ethylamino)ethyl)benzyl)-2-(4-methoxyphenyl)-1H-indol-5-ol;
1-(4-(2-(Cyclopropylamino)ethyl)benzyl)-3-fluoro-2-(o-tolyl)-1H-indol-5-ol;
3-Fluoro-2-(2-methoxyphenyl)-1-(4-(2-(propylamino)ethyl)benzyl)-1H-indol-5-ol;
1-(4-(2-(Cyclobutylamino)ethyl)benzyl)-2-(2,6-dimethylphenyl)-3-fluoro-1H-indol-5-ol;
2-(2,6-Dimethylphenyl)-1-(4-(2-(ethylamino)ethyl)benzyl)-3-fluoro-1H-indol-5-ol;
1-(4-(2-(Cyclopropylamino)ethyl)benzyl)-3-fluoro-2-(4-hydroxy-2-methylphenyl)-1H-indol-5-ol;
3-Fluoro-1-(4-(2-((2-fluoroethyl)amino)ethyl)benzyl)-2-(4-methoxy-2-methylphenyl)-1H-indol-5-ol;
3-Fluoro-1-(4-(2-((3-fluoropropyl)amino)ethyl)benzyl)-2-(4-methoxy-2-methylphenyl)-1H-indol-5-ol;
1-(4-(2-(Cyclopropylamino)ethyl)benzyl)-3-fluoro-2-(4-fluoro-2-methylphenyl)-1H-indol-5-ol;
3-Fluoro-2-(4-methoxy-2-methylphenyl)-1-(4-(2-(propylamino)ethyl)benzyl)-1H-indol-5-ol;
2-([1,1′-Biphenyl]-2-yl)-3-fluoro-1-(4-(2-(propylamino)ethyl)benzyl)-1H-indol-5-ol;
1-(4-(2-(Ethylamino)ethyl)benzyl)-3-fluoro-2-(o-tolyl)-1H-indol-5-ol;
1-(4-(2-(Cyclobutylamino)ethyl)benzyl)-3-fluoro-2-(o-tolyl)-1H-indol-5-ol;
3-Fluoro-1-(4-(2-(propylamino)ethyl)benzyl)-2-(o-tolyl)-1H-indol-5-ol;
1-(4-(2-(Butylamino)ethyl)benzyl)-3-fluoro-2-(o-tolyl)-1H-indol-5-ol;
3-Fluoro-1-(4-(2-((3-fluoropropyl)amino)ethyl)benzyl)-2-(o-tolyl)-1H-indol-5-ol;
3-Fluoro-1-(4-(2-((2-fluoroethyl)amino)ethyl)benzyl)-2-(o-tolyl)-1H-indol-5-ol;
1-(4-(2-(Cyclopropylamino)propyl)benzyl)-3-fluoro-2-(o-tolyl)-1H-indol-5-ol; 1-(4-(2-((Cyclopropylmethyl)amino)ethyl)benzyl)-3-fluoro-2-(2-(trifluoromethyl)phenyl)-1H-indol-5-ol;
1-(4-(2-(Cyclopropylamino)ethyl)benzyl)-3-fluoro-2-(2-(trifluoromethyl)phenyl)-1H-indol-5-ol;
1-(4-(2-(Ethylamino)ethyl)benzyl)-3-fluoro-2-(2-(trifluoromethyl)phenyl)-1H-indol-5-ol;
2-(2-Chlorophenyl)-1-(4-(2-(cyclopropylamino)ethyl)benzyl)-3-fluoro-1H-indol-5-ol;
N-Ethyl-2-(4-((8-fluoro-7-(o-tolyl)pyrrolo[3,2-e]indazol-6(3H)-yl)methyl)phenyl)ethan-1-amine;
N-(Cyclopropylmethyl)-2-(4-((8-fluoro-7-(o-tolyl)pyrrolo[3,2-e]indazol-6(3H)-yl)methyl)phenyl)ethan-1-amine;
N-(4-((8-Fluoro-7-(o-tolyl)pyrrolo[3,2-e]indazol-6(3H)-yl)methyl)phenethyl)cyclobutanamine;
N-(4-((8-Fluoro-7-(o-tolyl)pyrrolo[3,2-e]indazol-6(3H)-yl)methyl)phenethyl)cyclopropanamine;
N-(4-((8-fluoro-7-(o-tolyl)pyrrolo[3,2-e]indazol-6(3H)-yl)methyl)phenethyl)propan-1-amine;
3-Fluoro-N-(4-((8-fluoro-7-(o-tolyl)pyrrolo[3,2-e]indazol-6(3H)-yl)methyl)phenethyl)propan-1-amine;
(5R,6S)-5-(4-(2-(Ethylamino)ethyl)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-ol;
(5R,6S)-5-(4-(2-((Cyclopropylmethyl)amino)ethyl)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-ol;
(5R,6S)-5-(4-(2-(Ethylamino)ethyl)phenyl)-6-(o-tolyl)-5,6,7,8-tetrahydronaphthalen-2-ol;
(5R,6S)-5-(4-(2-((cyclopropylmethyl)amino)ethyl)phenyl)-6-(o-tolyl)-5,6,7,8-tetrahydronaphthalen-2-ol;
5-(4-(2-(Ethylamino)ethyl)phenyl)-6-(4-isopropylphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol;
6-(4-Isopropylphenyl)-5-(4-(2-(propylamino)ethyl)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol;
3-Fluoro-N-(4-((8-fluoro-7-(o-tolyl)pyrrolo[3,2-e]indazol-6(3)-yl)methyl)phenethyl)propan-1-amine;
5-(4-(2-((Cyclopropylmethyl)amino)ethyl)phenyl)-6-(4-isopropylphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol;
3-(4-(2-(Cyclopropylamino)ethyl)phenoxy)-2-(o-tolyl)benzo[b]thiophen-6-ol;
3-(4-(2-((Cyclopropylmethyl)amino)ethyl)phenoxy)-2-(o-tolyl)benzo[b]thiophen-6-ol;
3-(4-((1-Propylazetidin-3-ylidene)methyl)phenoxy)-2-(o-tolyl)benzo[b]thiophen-6-ol;
5-(4-(2-(Cyclopropylamino)ethyl)benzyl)-4-(o-tolyl)-2,3-dihydrobenzo[b]oxepin-8-ol; and
5-(4-(2-(Ethylamino)ethyl)benzyl)-4-(o-tolyl)-2,3-dihydrobenzo[b]oxepin-8-ol.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A pharmaceutical composition comprising a compound of any one of claims 1-28 and a pharmaceutically acceptable excipient.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method of treating a disease, syndrome, illness, or symptom associated with insufficient or overabundant estrogen levels in a mammal in need thereof, comprising administrating to said mammal an effective amount of a compound of any one of claims 1-28 or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method of treating a cancer selected from the group consisting of prostate cancer, breast cancer, endometrial cancer, lung cancer, hepatocellular cancer, lymphoma, multiple endocrine neoplasia, vaginal cancer, renal cancer, thyroid cancer, testicular cancer, leukemia, and ovarian cancer in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of any one of claims 1-28 or a pharmaceutically acceptable salt thereof.
